FindTrial
Sign In

Based on Zou Yanqin's "Tonifying Kidney Essence" approach for the treatment of Chronic Kidney Disease (CKD) stages 3-5 in the elderly: A real-world cohort study and exploration of its mechanism of action.

Based on Zou Yanqin's "Tonifying Kidney Essence" approach for the treatment of Chronic Kidney Disease (CKD) stages 3-5 in the elderly: A real-world cohort study and exploration of its mechanism of action.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026000981
Enrollment
Unknown
Registered
2026-04-16
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Interventions

Treatment group:Pattern differentiation therapy centered on the Kidney Essence Nourishing Formula.
Control Group:None

Sponsors

Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Meets the clinical diagnostic criteria for Chronic Kidney Disease (CKD) stages 3-5; 2. Meets the diagnostic criteria for Kidney Deficiency with Turbid Blood Stasis syndrome; 3. Age =60 years, gender unrestricted; 4. Informed consent, the process of obtaining the informed consent form should comply with GCP regulations.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing kidney transplantation, peritoneal dialysis, or hemodialysis treatment; 2. Patients with acute kidney failure; 3. Patients with severe primary diseases of the heart, brain, etc., such as malignant tumors or severe infections; 4. Patients with impaired consciousness, severe intellectual disabilities, or mental illness; 5. Patients with allergic constitutions or allergies to the drugs used in this study; 6. Patients currently receiving hormone therapy and/or immunosuppressive agents due to their primary kidney disease or other reasons; 7. Patients with other conditions, as judged by the investigator, that may reduce the likelihood of enrollment or complicate the enrollment process, such as frequently changing work environments that may lead to loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Incidence of outcome events;—

Secondary

MeasureTime frame
Serum Creatinine;Estimated glomerular filtration rate;Cystatin C;Urine albumin/creatinine ratio;hemoglobin;Uric acid;glycated hemoglobin;Triglyceride;Total Cholesterol;Low-Density Lipoprotein;High-Density Lipoprotein;Lipoprotein(a);High-sensitivity C-reactive protein;Serum potassium;blood calcium;blood phosphorus;Serum bicarbonate;Parathyroid Hormone;—

Countries

China

Contacts

Public ContactYi Lan

Jiangsu Provincial Hospital of Traditional Chinese Medicine

13382038280@qq.com13382038280

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026